Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|October 21, 2013
Cultivating a Career in Specialty Pharmacy
Specialty Pharmacy Times contributor Quintin Jessee discusses why he chose a career in specialty pharmacy and the new opportunities that are emerging in this industry.
Advertisement
Specialty Pharmacy Times contributor Quintin Jessee discusses why he chose a career in specialty pharmacy and the new opportunities that are emerging in this industry.
To watch more videos about specialty pharmacy, visit our
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5